BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), has been ranked 15 th on The Patent Board’s list of the top 67 biotechnology companies as determined by an assessment of the overall quality of each company’s patent portfolio. The Biotechnology Patent Scorecard is published quarterly in The Wall Street Journal and links a company’s patents to its core science and overall quality. The Patent Scorecard provides deeper insights into patent portfolios as measurable financial assets and drivers of market value.

BioSante appears on The Biotechnology Patent Scorecard for the first time, ranked on the basis of its acquisition of Cell Genesys (previously ranked 17th) in October of 2009 as well as its patents in women’s health and calcium phosphate portfolio. The merged company has new patents from Cell Genesys’s research on immunotherapies, and has a Research Intensity™ over three times the industry average.

Roche Holdings, Inc. was ranked 1 st on the list, followed by Biogen Idec, Inc., and Human Genome Sciences.

“We are gratified by The Patent Board’s recognition of our science and technology strength,” said Stephen M. Simes, BioSante’s president and CEO. “Our acquisition of Cell Genesys in late 2009 has resulted in an expansion of our product portfolio, especially in oncology products. Several of these cancer immunotherapies currently are in human clinical trials at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and are being conducted at no cost to BioSante. We acquired 95 patents and 85 patent applications that cover the newly acquired technologies. Our objective is to maximize the value of these products and technologies at minimal cost to BioSante.”

About The Patent Board

The Patent Board is the world’s leading business-based patent advisor to Fortune 500 companies, technology-based start-ups, law firms, investment banks, and governments. With four decades of experience, The Patent Board utilizes proprietary data, tools, and analytics to leverage patent-based IP as an asset class. The Patent Board is the official patent ratings partner for The Wall Street Journal, with a weekly Patent Scorecard column for the WSJ Market Data Center online and monthly publications in many leading business-based magazines. The Patent Board™ tracks and analyzes innovation, movement, and the business impact of patent assets across 17 industries on a global basis. The Patent Board has offices in Chicago and Philadelphia. For more information, visit The Patent Board’s website at www.PatentBoard.com.

About The Patent Board Indicators

Patents Granted – equals the number of U.S. patents granted in a given year, excluding design and other special-case inventions.

Science Strength™ - ranking measure to indicate how much a company uses science in building its patent portfolio with a combined measure of science and quantity.

Innovation Cycle Time™ - indicates whether a patent or patent portfolio is building off newer or older inventions (art).

Industry Impact™ - indicates the extent to which others are building upon a portfolio of issued US utility patents as compared to the total set of utility patents.

Technology Strength™ - ranking measure to indicate an overall strength of the company’s patent portfolio holdings with a combined measure of quality and quantity.

Research Intensity™ – indicates the extent to which a portfolio includes patents with above average Science Linkage as compared to the control group.

About BioSante Pharmaceuticals, Inc.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante’s lead products include LibiGel ® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals (NASDAQ: TEVA) and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3 billion. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), as a vaccine adjuvant, including for an H1N1 (swine flu) vaccine, and drug delivery. In addition, BioSante will seek opportunities for its GVAX cancer immunotherapies, 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.

Copyright Business Wire 2010